Floatz logo

Maplirpacept

Epithelial Ovarian Cancer

PfizerPhase 1/2Active
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
73/ 100

Competitive context

81 Active assets in the Epithelial Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Carboplatin
University of Washington
Phase 3BB
Inno-206
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3BB
Hycamtin
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Maplirpacept is also rated in:

diffuse large B-cell lymphomaDormant
CCC
Indicative ·
51 / 100
View asset →
ALK-positive large B-cell lymphomaDormant
CC
Indicative ·
45 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →